Equities research analysts forecast that Becton Dickinson and Co (NYSE:BDX) will report $2.60 earnings per share for the current fiscal quarter, Zacks Investment Research reports. Eight analysts have issued estimates for Becton Dickinson and’s earnings, with the lowest EPS estimate coming in at $2.54 and the highest estimate coming in at $2.65. Becton Dickinson and reported earnings per share of $2.30 in the same quarter last year, which suggests a positive year over year growth rate of 13%. The company is scheduled to report its next quarterly earnings report on Tuesday, May 1st.
According to Zacks, analysts expect that Becton Dickinson and will report full year earnings of $10.94 per share for the current year, with EPS estimates ranging from $10.85 to $11.00. For the next year, analysts anticipate that the business will post earnings of $12.60 per share, with EPS estimates ranging from $12.44 to $12.86. Zacks Investment Research’s earnings per share averages are an average based on a survey of analysts that that provide coverage for Becton Dickinson and.
Becton Dickinson and (NYSE:BDX) last posted its earnings results on Tuesday, February 6th. The medical instruments supplier reported $2.48 EPS for the quarter, topping analysts’ consensus estimates of $2.41 by $0.07. Becton Dickinson and had a net margin of 2.71% and a return on equity of 16.19%. The business had revenue of $3.08 billion for the quarter, compared to analysts’ expectations of $3.05 billion. During the same period in the previous year, the company posted $2.33 earnings per share. The business’s revenue for the quarter was up 5.4% compared to the same quarter last year.
Several research firms recently issued reports on BDX. Morgan Stanley upped their price target on shares of Becton Dickinson and from $245.00 to $250.00 and gave the company an “equal weight” rating in a report on Wednesday, February 7th. Piper Jaffray Companies reaffirmed an “overweight” rating and issued a $260.00 price target (up from $223.00) on shares of Becton Dickinson and in a report on Tuesday, February 6th. Zacks Investment Research raised shares of Becton Dickinson and from a “hold” rating to a “buy” rating and set a $259.00 price target on the stock in a report on Friday, January 19th. Bank of America reiterated a “buy” rating and set a $260.00 target price on shares of Becton Dickinson and in a research note on Friday, January 19th. Finally, Citigroup upgraded shares of Becton Dickinson and from a “sell” rating to a “neutral” rating in a research note on Friday, January 5th. Four research analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $237.27.
In related news, Director Timothy M. Ring sold 269,661 shares of the stock in a transaction that occurred on Thursday, February 8th. The stock was sold at an average price of $217.82, for a total value of $58,737,559.02. Following the transaction, the director now owns 295,753 shares in the company, valued at $64,420,918.46. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 1.00% of the stock is currently owned by corporate insiders.
Several institutional investors and hedge funds have recently bought and sold shares of the company. BlackRock Inc. raised its stake in Becton Dickinson and by 6.0% during the fourth quarter. BlackRock Inc. now owns 18,811,302 shares of the medical instruments supplier’s stock worth $4,026,750,000 after acquiring an additional 1,071,288 shares in the last quarter. State Street Corp raised its stake in Becton Dickinson and by 3.5% during the second quarter. State Street Corp now owns 10,270,221 shares of the medical instruments supplier’s stock worth $2,003,834,000 after acquiring an additional 342,873 shares in the last quarter. Franklin Resources Inc. raised its stake in Becton Dickinson and by 1.6% during the fourth quarter. Franklin Resources Inc. now owns 3,689,932 shares of the medical instruments supplier’s stock worth $789,867,000 after acquiring an additional 57,002 shares in the last quarter. Fundsmith LLP raised its stake in Becton Dickinson and by 0.3% during the second quarter. Fundsmith LLP now owns 2,302,590 shares of the medical instruments supplier’s stock worth $449,258,000 after acquiring an additional 5,977 shares in the last quarter. Finally, Geode Capital Management LLC raised its stake in Becton Dickinson and by 3.4% during the fourth quarter. Geode Capital Management LLC now owns 2,216,435 shares of the medical instruments supplier’s stock worth $473,373,000 after acquiring an additional 72,358 shares in the last quarter. 77.50% of the stock is owned by institutional investors.
Becton Dickinson and (BDX) traded down $2.10 during midday trading on Friday, hitting $220.77. 560,765 shares of the stock were exchanged, compared to its average volume of 1,608,499. The firm has a market capitalization of $58,680.00, a PE ratio of 1,575.21, a P/E/G ratio of 1.59 and a beta of 1.12. The company has a current ratio of 1.54, a quick ratio of 0.93 and a debt-to-equity ratio of 1.04. Becton Dickinson and has a twelve month low of $175.66 and a twelve month high of $248.39.
The firm also recently declared a quarterly dividend, which will be paid on Friday, March 30th. Shareholders of record on Friday, March 9th will be issued a $0.75 dividend. This represents a $3.00 dividend on an annualized basis and a yield of 1.36%. The ex-dividend date is Thursday, March 8th. Becton Dickinson and’s payout ratio is 2,142.86%.
ILLEGAL ACTIVITY NOTICE: “” was originally reported by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this piece can be read at https://www.thelincolnianonline.com/2018/02/20/612850.html.
Becton Dickinson and Company Profile
Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.